Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?
Tildrakizumab 200 mg is effective and safe for moderate-to-severe psoriasis, particularly in obese patients. These findings support its use as a long-term treatment option.
Authors
- Giovanni Palazzo
- Claudia Giofrè
- Eugenia Veronica Di Brizzi (ORCID: https://orcid.org/0000-0002-0278-2443)
- Massimiliano Nicolini
- Francesco Cusano
- Valeria Falcomatà
- Oriele Sarno
- Emanuela Gubinelli
- Leonardo Pescitelli (ORCID: https://orcid.org/0000-0002-5687-5485)
- Anna Balato (ORCID: https://orcid.org/0000-0001-5485-0172)
- Stefano Caccavale (ORCID: https://orcid.org/0000-0001-7433-9283)
- Rocco De Pasquale (ORCID: https://orcid.org/0000-0001-8644-8946)
- Giampiero Mazzocchetti
- Roberta Di Caprio (ORCID: https://orcid.org/0000-0002-0487-1327)
- Caterina Foti (ORCID: https://orcid.org/0000-0001-6196-9788)
- Rosa Valentina Puca
Institutions
- University of Sannio (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT)
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
- Istituto Dermopatico dell'Immacolata (IT)
- Azienda USL di Pescara (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Ospedale Civile di Venezia (IT)
- Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT)
- University of Florence (IT)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Dermatology Practical & Conceptual
- Published
- 2024-10-23
- DOI
- https://doi.org/10.5826/dpc.1404a284
- Citations
- 6
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.44